Hyperion Capital Advisors LP Makes New $728,000 Investment in West Pharmaceutical Services, Inc. $WST

Hyperion Capital Advisors LP bought a new stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 2,029 shares of the medical instruments supplier’s stock, valued at approximately $728,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of WST. BlackRock Inc. bought a new position in West Pharmaceutical Services in the second quarter valued at about $2,387,990,000. State Street Corp grew its stake in shares of West Pharmaceutical Services by 2.1% during the 2nd quarter. State Street Corp now owns 3,271,866 shares of the medical instruments supplier’s stock valued at $715,884,000 after purchasing an additional 68,330 shares during the period. Artisan Partners Limited Partnership increased its position in shares of West Pharmaceutical Services by 2.9% during the 4th quarter. Artisan Partners Limited Partnership now owns 2,850,401 shares of the medical instruments supplier’s stock valued at $784,259,000 after purchasing an additional 79,481 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of West Pharmaceutical Services during the 2nd quarter valued at about $733,733,000. Finally, Generation Investment Management LLP bought a new position in shares of West Pharmaceutical Services in the 2nd quarter worth approximately $728,168,000. 93.90% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Morgan Stanley raised their price objective on shares of West Pharmaceutical Services from $325.00 to $365.00 and gave the stock an “equal weight” rating in a report on Thursday, July 9th. KeyCorp upped their target price on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the company an “overweight” rating in a report on Thursday, July 2nd. Weiss Ratings upgraded shares of West Pharmaceutical Services from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, August 7th. Zacks Research cut shares of West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 12th. Finally, Stephens reissued an “overweight” rating and set a $360.00 price objective on shares of West Pharmaceutical Services in a research report on Tuesday, June 2nd. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $368.08.

West Pharmaceutical Services Stock Performance

WST opened at $353.33 on Tuesday. The company has a 50 day simple moving average of $349.06 and a two-hundred day simple moving average of $301.06. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.82 and a quick ratio of 2.12. The firm has a market cap of $24.87 billion, a P/E ratio of 45.24, a PEG ratio of 2.47 and a beta of 1.15. West Pharmaceutical Services, Inc. has a 1-year low of $223.83 and a 1-year high of $386.00.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, July 23rd. The medical instruments supplier reported $2.37 EPS for the quarter, beating the consensus estimate of $2.08 by $0.29. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The firm had revenue of $872.30 million for the quarter, compared to the consensus estimate of $839.98 million. During the same period last year, the firm earned $1.84 EPS. The company’s revenue was up 13.8% on a year-over-year basis. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. Equities analysts forecast that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th were issued a dividend of $0.22 per share. The ex-dividend date of this dividend was Wednesday, July 29th. This represents a $0.88 dividend on an annualized basis and a yield of 0.2%. West Pharmaceutical Services’s dividend payout ratio (DPR) is currently 11.27%.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.